Biotech News

Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure

Precision BioSciences (DTIL)Precision BioSciencesClinical readout

-Phase 1 ELIMINATE-B study successful, PBGENE-HBV Program Advancing to Phase 2- -PBGENE-HBV achieves target product profile at 0.4 mg/kg dose- -PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients at expected go-forward dose of 0.4 mg/kg; Durable and ongoing pgRNA loss in

Related news

Precision BioSciences

ARCUS Gene Editing Platform Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material. PBGENE-HBV PBGENE-HBV is a wholly...

Recent company news

Stock data

Close
6.91 USD
Market cap
163.07M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States